KTD
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Keytone Dairy Corporation Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
1
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Keytone Dairy Corporation Limited
π Performance
Price History
-63.08%
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.12
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in KTD
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in KTD
1292 days
KTD investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in KTD also invest in...
Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The firm cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. (Mernova) and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc. (Halucenex), it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.
π Share price
$0.01 AUD
Hazer Group Ltd. engages in the research and development of novel graphite, and hydrogen production technology. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-12-02. The Companyβs process enables the conversion of natural gas and similar feedstocks, into hydrogen and graphite, using iron ore as a process catalyst. Its Hazer Process focuses on savings for the hydrogen producer, as well as providing clean hydrogen with lower carbon dioxide emissions, enabling such hydrogen to be used in a range of developing clean energy applications, as well as in existing chemical processing industries. The HAZER Process produces synthetic graphite. The firm's markets include industrial hydrogen, hydrogen mobility and synthetic graphite. The company also has facilities, including a research and development lab and a fluid bed reactor pilot plant.
π Share price
$0.78 AUD
MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.
π Share price
$0.01 AUD
Redbubble Ltd. engages in the development and provision of online marketplace, where artists upload their designs and creative works. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-05-16. The firm owns and operates the global online marketplaces, Redbubble.com and TeePublic.com. These marketplaces facilitate the sale and purchase of art and designs for a range of products sold by independent creators to consumers. The products are produced and shipped by third-party service providers, such as product manufacturers, printers and shipping companies (collectively fulfillers). Through the Redbubble and TeePublic marketplaces, independent artists are able to profit from their creativity. Its product range includes clothing, stickers, phone cases, wall art, home and living, kids and babies, pets, accessories, stationery and office, and gifts. The company offers two types of phone cases, iPhone cases and Samsung Galaxy. Its wall art product range includes art board prints, art prints, canvas prints, framed prints, metal prints, mounted prints and other.
π Share price
$0.36 AUD
4DS Memory Ltd. operates as a semiconductor development company. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-12-09. The firm is engaged in the development of a non-volatile memory technology known as Interface Switching resistive random-access memory (ReRAM), for gigabyte storage class memory. Interface Switching ReRAM, an area-based ReRAM technology positioned for storage class memory in mobile devices and cloud data centers. The company owns a patented Internet protocol (IP) portfolio, comprising 32 United States patents granted and an additional one patent application, which have been developed in-house to create high-density storage class memory. In collaboration with imec in Belgium, the Company is developing a production-compatible process for the 300-millimeter production tools that memory makers use to fabricate high-density, high-volume memories to use in a production-compatible process to build a 4DS megabit memory.
π Share price
$0.03 AUD
Want more shares? Try these...